Michael Davidson, NewAmsterdam CEO
July 29, 2024 08:00 AM EDTUpdated 11:15 AM
Deals
R&D
Pharma

NewAms­ter­dam suc­ceeds in the first of three key piv­otal stud­ies, pro­vid­ing hope to a trou­bled car­dio class

Max Bayer

Pharma Reporter

NewAms­ter­dam Phar­ma aced the first in a cas­cade of Phase 3 read­outs, show­ing that its lead car­dio med­i­cine took down lev­els of bad cho­les­terol. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times